

HPV Prevention and Control Board

Alex Vorsters



HPV Prevention
and Control Board

www.hpvboard.org

Aims & Objectives

Aim

- To contribute to the prevention and control of HPV and HPV related diseases
- To generate, multiply and disseminate relevant information on HPV to a broad array of stakeholders

Objectives

- Provide evidence-based guidance on key technical and strategic issues by organizing two meetings per year i.e., 1) technical meeting and 2) country meeting
- Monitor the progress of HPV control programs at the country and regional levels.



[Health Topics ▾](#)[Countries ▾](#)[Newsroom ▾](#)[Emergencies ▾](#)[Data ▾](#)[About WHO ▾](#)[Home](#) / [Newsroom](#) / [Events](#) / [Detail](#) / Launch of the Global Strategy to Accelerate the Elimination of Cervical Cancer

To end cervical cancer



**7 out of 10 women
should be screened
by 35 years old.**

To end cervical cancer



**9 out of 10 women
identified with cervical
disease should be treated.**

To end cervical cancer



**9 out of 10 girls
should be vaccinated against
human papillomavirus (HPV).**

A multi-disciplinary Board formed by prominent experts

- Act in their personal capacity
- Are often affiliated with stakeholding partners
- This provides open and honest discussions
- Advisors and speakers at HPV Prevention & Control Board meetings are not paid
- No formal organisation with president, vice-president i.e., minimal bureaucratic structure

Advisors

- **Dr. Alex Vorsters**
 - *University of Antwerp, Belgium*
- **Prof. Dr. Anna Giuliano**
 - *Moffitt Cancer Center, USA*
- **Prof. Dr. Eduardo Franco**
 - *McGill University, Canada*
- **Dr. Heidi Larson**
 - *London School of Hygiene and Tropical Medicine, UK*
- **Dr. Kate Cuschieri**
 - *Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, Scotland, UK*
- **Prof. Mamadou Diop**
 - *Joliot Curie Cancer institute of Dakar, Senegal*
- **Dr. Marc Arbyn**
 - *Scientific Institute of Public Health, Belgium*
- **Dr. Mark Kane**
 - *Consultant USA*
- **Prof. Dr. Mario Poljak**
 - *Institute of Microbiology and Immunology, clinical Microbiology, Slovenia*
- **Prof. Dr. Margaret Stanley**
 - *University of Cambridge, UK*



A multi-disciplinary Board formed by prominent experts

Advisors

- **Prof. dr. Mira Kojouharova**
 - *National Centre of Infectious and Parasitic Diseases (NCIPD), Bulgaria*
- **Prof. Dr. Narendra Kumar Arora**
 - *The INCLEN Trust International*
- **Prof. dr. Nubia Muñoz**
 - *The National Cancer Institute of Colombia*
- **Prof. Dr. Pierre Van Damme**
 - *University of Antwerp, Belgium*
- **Prof. Dr. Paolo Bonanni**
 - *University of Florence, Italy*
- **Dr. Silvia de Sanjosé**
 - *Catalan Institute of Oncology (ICO), Spain*
- **Dr. Sharon Hanley**
 - *Hokkaido University, Japan*
- **Prof. Dr. Susanne Krüger Kjaer**
 - *University of Copenhagen, Denmark*
- **Prof. Suzanne Garland**
 - *University of Melbourne, Australia*
- **Dr. Xavier Bosch**
 - *Catalan Institute of Oncology (ICO), Spain*

Observers

- Dr. Iacobo Baussano, IACR
- Mr. Tarik Derrough, ECDC
- Dr. Liudmila Mosina , WHO Euro
- Dr. Lauri Markowitz, CDC, USA





HPV Prevention and Control Board

www.hpvboard.org



University
of Antwerp

HPV Board Secretariat

- Personnel involved*:
 - Brenda Janssens
 - Dur-e-Nayab Waheed
 - Xenia Mikulla
 - Felix Ricardo Burdier Custodio
- Executive Secretary: Alex Vorsters
- Located within the facilities of the Centre for the Evaluation of Vaccination (CEV), University of Antwerp




**: Total involvement of 2.0 FTE, all member have other tasks at the department.*



Secretariat Activities

- Preparation and organisation of meetings
- Publications
- Media activities
- Website: www.hpvboard.org
- Participation in third party meetings
- All financial issues are done by the rules of the University of Antwerp



Permanent intensive communication between HPV board members and secretariat



HPV Prevention and Control Board Kick-Off meeting 1-2 December 2015



Barriers in HPV Vaccination & cervical screening programmes.
27-28 June 2016 Meeting Antwerp



**Country meeting: 'Prevention and control of HPV and HPV related cancers in Denmark: lessons learnt and the way forward'
17-18 November 2016, Copenhagen, Denmark**



**Technical meeting: Symposium: Building Trust, Managing Risk:
Vaccine Confidence and Human Papillomavirus Vaccination,
7-8 June 2017, London, UK**



Country meeting: 'Prevention and control of HPV and HPV related cancers in Ireland and the UK: lessons learnt and the way forward'
30th November – 1 December 2017, Dublin, Ireland.



As the meeting was held in Dublin, we had the honour to have Mr Simon Harris, Minister of Health of Ireland, open the meeting. In his [speech](#), he reiterated his full support to the HPV vaccination programme in Ireland and emphasized the role of qualified medical professionals



The role of HCP in HPV vaccination and screening programme implementation - Prevention and control of HPV and HPV related cancers in Romania, 15 & 16 May 2018

Short Videos



Benefits and Safety of HPV Vaccination
- Dr. Xavier Bosch



USA - Helping healthcare providers
improve HPV communication - Dr. Noel
Brewer



Prevention and control of HPV and HPV related cancers in Colombia: Lessons learnt and the way forward. November 2018




HPV Vaccination of Adults : Impact, Opportunities and Challenges. 14 & 15 Nov 2019

Videos

HPV VACCINATION
OF ADULTS
14-15 November, 2019
Antwerp, Belgium

SESSION #2
HPV IMMUNOLOGICAL DYNAMICS
AT MUCOSAL & SYSTEMIC LEVEL

POTENTIAL BENEFITS OF HPV VACCINATION
IN SEXUALLY ACTIVE WOMEN
by John Schiller




HPV Prevention
and Control Board
www.hpvboard.org

Potential Benefits of HPV Vaccine in sexually active women: delivering the promise - John Schiller

HPV VACCINATION
OF ADULTS
14-15 November, 2019
Antwerp, Belgium

SESSION #3
LIMITATION & ELIMINATION GOAL

TOWARDS CERVICAL CANCER ELIMINATION
THE CONTEXT OF HPV VACCINATION
by Paul Bloem



HPV Prevention
and Control Board
www.hpvboard.org

Towards cervical cancer elimination: the context of HPV Vaccination - Paul Bloem



Challenges in the HPV Screening Landscape, Triage of Screening
Positive Samples, and Screening in the Era of Vaccination.
August 2020 Online Meeting.

Impact of COVID-19 on Cervical Cancer Screening, Treatment and
Vaccination.
November 2020 - Online Technical Meeting

Reinforcing Access to HPV Vaccination & Cervical Cancer Screening
and Treatment.
April 2021 - Online Technical Meeting





HPV Prevention and Control Board Website

 University of Antwerp

Login ▾

🏠 HPV PREVENTION AND CONTROL BOARD



About us Meetings Resources Vaccine safety News

HPV Prevention and Control Board



The HPV Prevention and Control Board was created in December 2015 with the aim to share relevant information on HPV with a broad array of stakeholders.

The HPV Prevention and Control Board is composed of a group of experts, who set the strategy and define the actions.

The HPV Board has a permanent executive secretariat, located at the [Vaccine & Infectious Disease Institute \(VAXINFECTIO\)](#) of the University of Antwerp.



Publications in Scientific Journals

Papillomavirus Research:


Manuscript on 'Overcoming barriers in HPV vaccination and screening programs'

Vaccine:


HPV Immunization programs: Ensuring their sustainability and resilience.

Papilloma Virus Research:

The Role of healthcare providers in HPV Vaccination Programs- A meeting report




Papillomavirus Research
Volume 4, December 2017, Pages 45-53
[open access](#)



Overcoming barriers in HPV vaccination and screening programs

Alex Vorsters ^a ✉, Marc Arbyn ^b, Marc Baay ^c, Xavier Bosch ^d, Silvia de Sanjosé ^{d, e}, Sharon Hanley ^f, Emilie Karafillakis ^g, Pier Luigi Lopalco ^h, Kevin G. Pollock ⁱ, Joanne Yarwood ^j, Pierre Van Damme ^a


Vaccine 36 (2018) 5219–5221



Contents lists available at [ScienceDirect](#)

Vaccine

journal homepage: www.elsevier.com/locate/vaccine





Commentary

HPV immunization programs: Ensuring their sustainability and resilience


Alex Vorsters ^{*}, Pierre Van Damme

Centre for the Evaluation of Vaccination, University of Antwerp, Belgium





Papillomavirus Research
Volume 8, December 2019, 100183



The role of healthcare providers in HPV vaccination programs – A meeting report



Publications in Scientific Journals

BMC Proceedings:

Prevention and control of HPV infection and HPV-related cancers in Colombia.

Vorsters et al. *BMC Proceedings* 2020, **14**(Suppl 9):8
<https://doi.org/10.1186/s12919-020-00192-2>

BMC Proceedings

MEETING REPORT

Open Access

Prevention and control of HPV infection and HPV-related cancers in Colombia- a meeting report



Alex Vorsters^{1*}, Francesc Xavier Bosch^{2,3}, Paolo Bonanni⁴, Eduardo L. Franco⁵, Marc Baay⁶, Clarissa Simas⁷, Dur-e-Nayab Waheed¹, Carlos Castro⁸, Raul Murillo⁹, Lina Trujillo¹⁰, Carolina Wiesner¹⁰ and Nubia Muñoz¹⁰

From Prevention and control of HPV and HPV related cancers in Colombia: Lessons learnt and the way forward Bogota, Colombia. 15-16 November 2018

Acta Dermatovenereologica

Impact of the COVID-19 pandemic on human papillomavirus-based testing services to support cervical cancer screening

Acta Dermatovenereol APA

Acta Dermatovenereologica
Alpina, Pannonica et Adriatica

2021;30:21-26
doi: 10.15570/actaapa.2021.5

Impact of the COVID-19 pandemic on human papillomavirus-based testing services to support cervical cancer screening

Mario Poljak¹, Kate Cuschieri², Dur-e-Nayab Waheed³, Marc Baay⁴, Alex Vorsters³

¹Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. ²Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, NHS Lothian Scotland, Edinburgh, United Kingdom. ³Centre for Evaluation of Vaccination, Vaccine and Infectious Diseases Institute, University of Antwerp, Wilrijk, Belgium. ⁴Pg5 Epidemiology & Pharmacovigilance, Leuven, Belgium.



Publications in Scientific Journals

Preventive Medicine 156 (2022) 106960



Contents lists available at [ScienceDirect](#)

Preventive Medicine

journal homepage: www.elsevier.com/locate/ypmed



HPV prevention and control – The way forward

Alex Vorsters^{a,*}, F. Xavier Bosch^{b,f}, Mario Poljak^c, Dur-e-Nayab Waheed^a, Margaret Stanley^d, Suzanne M. Garland^e, on behalf of the HPV Prevention and Control Board and the International Papillomavirus Society (IPVS)

^a Center for the Evaluation of Vaccination & HPV Prevention and Control Board, University of Antwerp, Antwerp, Belgium

^b Cancer Epidemiology Research Program, IDIBELL, Catalan Institute of Oncology, L'Hospitalet De Llobregat, Barcelona, Spain

^c Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

^d Department of Pathology, University of Cambridge, United Kingdom

^e Department of Obstetrics and Gynaecology, University of Melbourne, Centre Women's Infectious Diseases Research, Royal Women's Hospital, Murdoch Children's Research Institute, Australia

^f Open University of Catalonia, Barcelona, Spain

ARTICLE INFO

Keywords

HPV
Prevention and control
Cervical cancer
COVID-19 pandemic
Elimination
Screening
Vaccination

ABSTRACT

The global confrontation with COVID-19 has not only diverted current healthcare resources to deal with the infection but has also resulted in increased resources in the areas of testing and screening, as well as educating most of the global public of the benefits of vaccination. When the COVID-19 pandemic eventually recedes, the opportunity must not be missed to ensure that these newly created resources are maintained and redeployed for use in testing and immunisation against other vaccine-preventable infectious diseases. A notable example is infection by human papillomavirus (HPV), the commonest sexually transmitted human virus and the leading cause of a variety of cancers in both men and women, such as cervical, head and neck, anal, vaginal, vulvar and



Background Document



Technical Meeting

HPV prevention and control in People Living With HIV Benefits and Challenges of Immunobridging trials DNA Methylation as a Triage Tool for Cervical Cancer Screening

2 - 3 June, 2022
Antwerp, Belgium

BACKGROUND DOCUMENT

DRAFT

Document will be finalized after the meeting

Dur-e-Nayab Waheed and Alex Vorsters

HPV Prevention & Control Board

Executive Secretariat, Vaccine and Infectious disease Institute, University of Antwerp, Campus Drie Eiken,
Universiteitsplein 1, 2610 Antwerp, Belgium.

Contents

Part 1: Ovid/Medline Search by Topic	2
HPV prevention and control in HIV positives	3
Immunobridging	15
HPV and DNA methylation	21
Part 2: Bibliography of Speakers	34
Aimee R. Kreimer, Senior Investigator, Infections & Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, NCI	35
Carina Eklund, Center for cervical cancer prevention, Karolinska Institute, Stockholm, Sweden	35
Chris JLM. Meijer, Professor of Pathology, Department of Pathology, Amsterdam University Medical Center (UMC), Location VUMC, Netherlands	35
Deborah Watson-Jones, Professor of Clinical Epidemiology and International Health, Mwanza Intervention Trials Unit (MITU)/ National Mwanza, Tanzania, National Institute for Medical Research (NIMR) and the London School of Hygiene and Tropical Medicine (LSHTM)	36
Daniëlle Heideman, Clinical Scientist in Molecular Pathology and Associate Professor, Department Pathology, Amsterdam UMC Department of Pathology, Amsterdam The Netherlands	37
Filipe Colaco Mariz, PhD/Research Assistant, German Cancer Research Center (DKFZ)	38
Gary Clifford, Deputy Head, Branch of Early Detection, Prevention and Infections, International Agency for Research on Cancer (IARC), Lyon, France	38
Helen Kelly, Epidemiologist, Associate Professor, London School of Hygiene and Tropical Medicine, National Cancer Institute	39
Iacopo Baussano, Scientist, Team Leader of the Public Health Decision Modelling Team, International Agency for Research on Cancer	40
Jack Cuzick, Head of Cancer Prevention Section, Wolfson Institute of Public Health	40
Joel Palefsky, Professor of Medicine, University of California, San Francisco, USA	41
Johannes Berkhof, Professor, Amsterdam UMC, Netherlands	41
Karolina Louvanto, MD, PhD, Tenure track Professor and Deputy Chief of Obstetrics and Gynecology, Tampere University and Tampere University Hospital, Finland	42
Mariam El-Zein, Associate Director for Research, Division of Cancer Epidemiology, McGill University	43
Paul Bloem, Technical Officer, HPV vaccine impact lead, Department of Immunization, Vaccines and Biologicals (IVB), WHO, Geneva	44
PART 3: HPV PREVENTION AND CONTROL BOARD OUTPUT	46

South Asia Meeting 13 – 15 Dec 2022; Delhi, India

- Provide an overview of epidemiological situation of cervical cancer disease burden in the region
- Provide an overview of health information systems in the countries
- Discuss HPV prevention and control measure in the region
- Discuss sustainable introduction of HPV vaccination programs
- Discuss progress and challenges in the region on HPV prevention and control
- Discuss sustainable platforms for introduction, lessons learnt from different states within the countries, monitoring systems, barriers to overcome, and the way forward.
- Discuss cervical cancer screening programs, barriers and steps needed to strengthen cervical cancer control/ HPV related cancers

Thank you for your attention



VAXINFECTIO
Vaccine & Infectious Disease Institute
University of Antwerp